Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

Karin BeelenMark OpdamTesa SeversonRutger KoornstraAndrew VincentJelle WesselingJoyce SandersJan VermorkenPaul van DiestSabine C Linn

Published in: BMC cancer (2018)

Postmenopausal breast cancer patients with high Ki67 counts do significantly benefit from adjuvant tamoxifen, while those with high mitotic count do not. Mitotic count is a better selection marker for reduced tamoxifen benefit than Ki67.

Keyphrases

peripheral blood
cell cycle
breast cancer cells
estrogen receptor
positive breast cancer
neoadjuvant chemotherapy
bone mineral density
early stage
breast cancer risk
cell proliferation
squamous cell carcinoma
postmenopausal women
body composition
lymph node
locally advanced